Jounce Therapeutics (NASDAQ:JNCE) issued its quarterly earnings results on Thursday. The company reported $2.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.66, Fidelity Earnings reports. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. The firm had revenue of $119.45 million for the quarter, compared to analyst estimates of $99.97 million.
JNCE traded up $0.06 during trading on Friday, hitting $4.06. The company’s stock had a trading volume of 211,300 shares, compared to its average volume of 175,348. The firm has a market capitalization of $124.67 million, a P/E ratio of -4.83 and a beta of 3.51. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.20. The stock’s fifty day moving average price is $3.49 and its 200-day moving average price is $4.28. Jounce Therapeutics has a twelve month low of $2.66 and a twelve month high of $7.35.
Several equities analysts have issued reports on JNCE shares. ValuEngine lowered Jounce Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 29th. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Saturday. Finally, JPMorgan Chase & Co. reissued a “sell” rating on shares of Jounce Therapeutics in a research note on Sunday, August 11th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. Jounce Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.75.
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.